Jubilant Pharmo's June 2026 net sales rise 17.29% YoY to Rs 2,229.4 crore

Despite this growth in topline, the company’s net profit sharply declined by 45.09% year-on-year, falling to Rs 56.50 crore from Rs 102.90 crore in the corresponding quarter of the previous year. Jubilant Pharmova’s EBITDA for the June 2026 quarter stood at Rs 267.90 crore, which marks an 11.17% decrease from Rs 301.60 crore reported a year ago.

Employee costs and other expenses contributed notably to the overall expenditure. The company’s employee cost rose to Rs 753.50 crore from Rs 591.10 crore in June 2025, while other expenses increased to Rs 479.20 crore compared to Rs 401.80 crore in the previous year. Consumption of raw materials for the quarter also climbed to Rs 638.30 crore, up from Rs 520.50 crore.

The profit and loss before tax for the June 2026 quarter came in at Rs 86.40 crore, down from Rs 154.50 crore in June 2025. The company’s interest expenses increased to Rs 54.20 crore from Rs 49.00 crore a year ago. For the same period, depreciation costs also saw a rise, reaching Rs 127.30 crore from Rs 98.10 crore.

In terms of earnings per share, the company reported a basic EPS of Rs 3.57 for June 2026, a substantial decrease from Rs 6.49 in June 2025. Diluted EPS followed a similar trajectory, falling to Rs 3.56 from last year’s Rs 6.47.

Looking at the company’s stock performance, Jubilant Pharmova shares closed at Rs 871.05 on August 19, 2026, on the NSE. Over the last six months, the stock has delivered a marginal negative return of -0.17%, and has dropped by 19.65% over the past twelve months.

The results underscore a period of topline expansion juxtaposed with margin pressures, driven by rising costs and higher expenses impacting profitability. The detailed results were compiled from consolidated financial statements for the group, and all data is sourced from Dion Global Solutions Limited and Moneycontrol.